Detection of direct oral anticoagulants with ClotPro

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00015302

Enrollment

Registered

2018-08-27

Start date

2018-09-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D68

Interventions

Group 1: The new oral anticoagulants dabigatran, edoxaban and rivaroxaban, as well as marcumar and heparin are to be investigated by rotation thrombelastometry / graphy (ClotPro). For this purpose, ne

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age > 18 years Intake of anticoagulation Informed consent

Exclusion criteria

Exclusion criteria: Age < 18 years Coagulation disorder Refusal of the patient

Design outcomes

Primary

Measure	Time frame
Change in specific tests ECATEST® and RVV® in contrast to blood samples without direct oral anticoagulant (doac).	—

Secondary

Measure	Time frame
Change in universal tests EXTEST and INTEST in contrast to blood samples without doac.	—

Countries

Germany

Contacts

Public ContactSimon Schäfer

Klinik für Anästhesiologie, Klinikum der Universität München, LMU München

simon.schaefer@med.uni-muenchen.de089440081142

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 23, 2026